Ac immune reports second quarter 2025 financial results and provides a corporate update

Ac immune reports second quarter 2025 financial results and provides a corporate update three active immunotherapies for precision prevention of neurodegeneration progressing through phase 2 clinical development aci-7104.056 anti-alpha-synuclein active immunotherapy in parkinson's disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing phase 2 vacsyn reported in april, with further data to come in h2 2025 third alzheimer's disease cohort (ad3) in the phase 2 abate trial of anti-abeta aci-24.060 to reach 12 months of treatment in december 2025, with interim results expected early 2026 small molecule nlrp3 program now in ind-enabling studies, highlighting promise in early-stage pipeline cash resources of chf 127.1 million (usd157.6 million) as of june 30, 2025, provide funding into q1 2027 excluding any potential milestone payments lausanne, switzerland, august 5, 2025 -- ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended june 30, 2025, and provided a corporate update. dr. andrea pfeifer, ceo of ac immune sa, commented: “ac immune is continuing to progress toward precision prevention of neurodegenerative diseases as we approach multiple value-inflection points through the rest of 2025 and beyond.
ACIU Ratings Summary
ACIU Quant Ranking